Abstract
The activity of RU29246, the active metabolite of the oral cephalosporin ester HR916, was compared in a multicenter study with that of the four oral beta-lactam antibiotics cephalexin, cefaclor, cefixime and amoxicillin/clavulanate (amoxicillin/CA). RU29246 was generally 2- to 8-fold more active than the other oral cephalosporins and comparable to amoxicillin/CA against staphylococci, and was the most active cephalosporin against group B streptococci. All four cephalosporins were ineffective against enterococci. RU29246 was the only cephalosporin consistently active againstAcinetobacter, but all beta-lactam antibiotics had poor activity againstPseudomonas spp. andXanthomonas maltophilia. RU29246 was comparable to cefixime and more active than the other cephalosporins against members of the familyEnterobacteriaceae. However, all of the antibiotics had poor activity againstEnterobacter cloacae andSerratia marcescens. Quality control reference ranges for the quality control organismsStaphylococcus aureus ATCC 29213 andEscherichia coli ATCC 25922 are proposed for the broth dilution method based on data derived from this multicenter study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Inamoto Y, Chiba T, Kamimura T, Takaya T FK482, a new orally active cephalosporin. Synthesis and biological properties. Journal of Antibiotics 1988, 41: 828–830.
Jones RN Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cephems. Antimicrobic Newsletter 1988, 5: 1–7.
Jones RN, Barry AL Preliminary in vitro studies of BMY-28232, the active metabolite of the BMY-28271 cephalosporin ester. Journal of Antimicrobial Chemotherapy 1989, 23: 654–657.
Mine Y, Kamimura T, Watanabe Y, Tawara S, Matsumoto Y, Shibayama F, Kikuchi H, Takaya T In vitro antibacterial activity of FK482, a new orally active cephalosporin. Journal of Antibiotics 1988, 41: 1873–1889.
Neu HC, Saha G, Chin NX Comparative in vitro activity and β-lactamase stability of FK482, a new oral cephalosporin. Antimicrobial Agents and Chemotherapy 1989, 33: 1795–1900.
Tamura A, Okamoto R, Yoshida T, Yamamoto H, Kondo S, Inoue M, Mitsuhashi S In vitro and in vivo antibacterial activities of ME 1207, a new oral cephalosporin. Antimicrobial Agents and Chemotherapy 1988, 32: 1421–1426.
Wise R, Andrews JM, Ashby JP, Thornber D In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents. Antimicrobial Agents and Chemotherapy 1990, 34: 813–818.
Jones RN, Erwin ME, Barrett MS, Briggs BM, Johnson DM: In vitro activity of RU29246, the metabolite of a new HR916 cephalosporin ester. Diagnostic Microbiology and Infectious Diseases 1991.
Jones RN, Erwin ME, Barrett MS: Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, RU29246) againstLegionella species. Diagnostic Microbiology and Infectious Diseases 1991.
National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed; approved standard. NCCLS document M7-A2. National Committee for Clinical Laboratory Standards, Villanova, PA, 1990.
National Committee for Clinical Laboratory Standards Development of in vitro susceptibility testing criteria and quality control parameters. NCCLS document M23-T. National Committee for Clinical Laboratory Standards, Villanova, PA, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murray, P.R., Allen, S.D., Erwin, M.E. et al. Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis. 10, 776–781 (1991). https://doi.org/10.1007/BF01972510
Issue Date:
DOI: https://doi.org/10.1007/BF01972510